ReviewMolecules (Basel, Switzerland)2026
USAG-1/SOSTDC1 as a Candidate Target for Periodontal Regeneration: Biological Rationale, Knowledge Gaps, and Future Directions.
Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUterine Sensitization-Associated Gene-1 (USAG-1), also known as SOSTDC1, is a bifunctional antagonist of bone morphogenetic protein (BMP) and Wnt signalling-two pathways that are central not only to tooth development but to the entire repertoire of periodontal tissue biology. Current periodontal regenerative therapy relies on exogenous BMP delivery and barrier membranes, approaches with significant limitations in predictability and tissue specificity. The recent entry of anti-USAG-1 antibody therapy into early-phase human clinical trials, with congenital tooth agenesis as the lead indication, raises the question of whether targeted USAG-1 inhibition could be repurposed for periodontal regeneration. PURPOSE: This perspective examines the biological rationale for USAG-1 as a target in periodontal regeneration, maps the plausible mechanisms through which its inhibition could restore cementum, periodontal ligament (PDL), and alveolar bone, and outlines the conditions and research agenda under which such an approach could be clinically developed.
conclusionsUSAG-1 transcripts have been reported in adult gingival tissues, and USAG-1 antagonises BMP and Wnt signals that are implicated in cementogenesis, PDL fibre formation, and alveolar bone homeostasis. Its inhibition is proposed as a biologically plausible, hypothesis-generating strategy for amplifying endogenous regenerative signalling in the periodontium, which might differ from, and could potentially complement, existing regenerative protocols; neither possibility has yet been tested. Realising this potential will require localised delivery strategies, validated biomarker endpoints, and controlled trials embedded in the framework of the EFP S3 stepwise treatment algorithm. Direct experimental evidence that USAG-1 inhibition promotes periodontal regeneration is currently lacking; the case advanced here is inferential and hypothesis-generating, not a demonstrated therapeutic effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.